The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.

Find Out What It Is Right Here.

AMAM Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.10%

Insider Buying (Last 12 Months): $26,010,339.85

Insider Selling (Last 12 Months): $0.00

Ambrx Biopharma Insider Trading History Chart

Ambrx Biopharma Share Price & Price History

^$14.92

▲ +0.39 (2.68%)

As of 06/2/2023 01:00 AM ET

Days: 30 | 90 | 365

27 U.S. Cities Where Stocks Yield 26% a Year

From Investing Daily | Ad

What’s the highest-yielding stock you’ve ever owned?

The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

Get in on the action here.

Ambrx Biopharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/19/2023	Cormorant Asset Management, Lp	Major Shareholder	Buy	135,850	$11.15	$1,514,727.50	9,485,714
4/17/2023	Cormorant Asset Management, Lp	Major Shareholder	Buy	562,121	$10.67	$5,997,831.07	62,097,896
4/13/2023	Cormorant Asset Management, Lp	Major Shareholder	Buy	1,193,808	$9.16	$10,935,281.28	60,693,808
3/16/2023	Cormorant Asset Management, Lp	Major Shareholder	Buy	500,000	$10.15	$5,075,000.00	53,500,000
3/14/2023	Cormorant Asset Management, Lp	Major Shareholder	Buy	250,000	$9.95	$2,487,500.00	52,750,000

The Ultimate Passive Income Play

From The Oxford Club | Ad

>>>

SEC Filings (Institutional Ownership Changes) for Ambrx Biopharma (NYSE:AMAM)

43.14% of Ambrx Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Ambrx Biopharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/16/2023	Squarepoint Ops LLC	17,511	$0.16M	0.0%	N/A	0.045%
5/15/2023	Schonfeld Strategic Advisors LLC	78,200	$0.70M	0.0%	N/A	0.202%
5/15/2023	Darwin Global Management Ltd.	11,304,573	$100.84M	27.6%	+49.0%	29.259%
5/15/2023	Nomura Holdings Inc.	57,268	$0.51M	0.0%	N/A	0.148%
5/15/2023	Commodore Capital LP	4,803,447	$42.85M	6.5%	N/A	12.433%
5/15/2023	Price T Rowe Associates Inc. MD	210,627	$1.88M	0.0%	N/A	0.545%
5/15/2023	Ghost Tree Capital LLC	250,000	$2.23M	0.7%	N/A	0.647%
5/15/2023	Farallon Capital Management LLC	361,000	$3.22M	0.0%	N/A	0.934%
5/11/2023	FMR LLC	2,210,618	$19.72M	0.0%	-18.0%	5.721%
5/11/2023	ExodusPoint Capital Management LP	19,497	$0.17M	0.0%	N/A	0.050%
5/10/2023	Tocqueville Asset Management L.P.	12,500	$0.11M	0.0%	N/A	0.032%
5/9/2023	Tower Research Capital LLC TRC	20,440	$0.18M	0.0%	+681,233.3%	0.053%
4/28/2023	Fosun International Ltd	249,190	$2.22M	0.2%	-87.1%	0.645%
3/15/2023	B. Riley Wealth Advisors Inc.	20,000	$45K	0.0%	N/A	0.052%
2/21/2023	B. Riley Wealth Advisors Inc.	20,000	$45K	0.0%	N/A	0.052%
2/15/2023	Millennium Management LLC	18,793	$43K	0.0%	-83.5%	0.049%
2/14/2023	Alpine Global Management LLC	46,723	$0.11M	0.0%	N/A	0.121%
2/13/2023	Renaissance Technologies LLC	32,500	$74K	0.0%	-49.2%	0.084%
11/14/2022	Royal Bank of Canada	42,453	$46K	0.0%	N/A	0.110%
11/14/2022	Cormorant Asset Management LP	2,336,389	$2.52M	0.2%	-6.0%	6.050%
11/14/2022	Renaissance Technologies LLC	64,000	$69K	0.0%	+481.8%	0.166%
8/13/2022	Renaissance Technologies LLC	11,000	$29K	0.0%	-51.3%	0.029%
8/12/2022	FMR LLC	3,857,679	$10.22M	0.0%	+0.8%	9.997%
5/16/2022	Suvretta Capital Management LLC	1,491,832	$6.15M	0.2%	+41.0%	3.866%
5/13/2022	Renaissance Technologies LLC	22,600	$93K	0.0%	+91.5%	0.059%
5/12/2022	BlackRock Inc.	2,851,486	$11.75M	0.0%	-0.6%	7.389%
2/15/2022	Adage Capital Partners GP L.L.C.	1,923,700	$17.37M	0.0%	+5.3%	5.107%
2/14/2022	Suvretta Capital Management LLC	1,057,735	$9.55M	0.2%	N/A	2.808%
11/15/2021	Tudor Investment Corp Et Al	20,143	$0.27M	0.0%	-66.4%	0.053%
11/12/2021	Ghisallo Capital Management LLC	15,000	$0.20M	0.0%	-62.5%	0.040%
11/9/2021	BlackRock Inc.	820,221	$11.07M	0.0%	-3.6%	2.177%
8/25/2021	Marshall Wace North America L.P.	32,648	$0.64M	0.0%	N/A	0.087%
8/17/2021	Millennium Management LLC	144,092	$2.82M	0.0%	N/A	0.383%
8/17/2021	Octagon Capital Advisors LP	450,000	$8.82M	1.8%	N/A	1.195%
8/17/2021	Boothbay Fund Management LLC	13,422	$0.26M	0.0%	N/A	0.036%
8/17/2021	Caas Capital Management LP	40,000	$0.78M	0.0%	N/A	0.106%
8/16/2021	Tudor Investment Corp Et Al	60,000	$1.18M	0.0%	N/A	0.159%
8/13/2021	FMR LLC	3,766,940	$68.73M	0.0%	N/A	10.000%
8/12/2021	Fosun International Ltd	1,932,591	$37.88M	2.2%	N/A	5.130%
8/12/2021	Monashee Investment Management LLC	110,000	$2.16M	0.3%	N/A	0.292%
8/11/2021	BlackRock Inc.	850,676	$16.67M	0.0%	N/A	2.258%
7/30/2021	Alliancebernstein L.P.	70,000	$1.37M	0.0%	N/A	0.186%

Data available starting January 2016

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Today's Range

Now: $14.92

$14.36

$15.25

50 Day Range

MA: $11.22

$7.66

$14.97

52 Week Range

Now: $14.92

$0.38

$15.29

Volume

370,321 shs

Average Volume

2,966,759 shs

Market Capitalization

$576.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Ambrx Biopharma?: Ambrx Biopharma's top insider investors include:
Cormorant Asset Management, Lp (Major Shareholder)
Learn More about top insider investors at Ambrx Biopharma.
Who are the major institutional investors of Ambrx Biopharma?: Ambrx Biopharma's top institutional investors include:
Darwin Global Management Ltd. — 29.26%
Commodore Capital LP — 12.43%
FMR LLC — 5.72%
Farallon Capital Management LLC — 0.93%
Ghost Tree Capital LLC — 0.65%
Fosun International Ltd — 0.64%
Learn More about top institutional investors of Ambrx Biopharma stock.
Which major investors are selling Ambrx Biopharma stock?: Within the previous quarter, AMAM stock was sold by these institutional investors:
Fosun International Ltd
FMR LLC
Which major investors are buying Ambrx Biopharma stock?: Within the previous quarter, AMAM stock was acquired by institutional investors including:
Commodore Capital LP
Darwin Global Management Ltd.
Farallon Capital Management LLC
Ghost Tree Capital LLC
Price T Rowe Associates Inc. MD
Schonfeld Strategic Advisors LLC
Nomura Holdings Inc.
Simplex Trading LLC